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The human body is colonized by a vast number of microorganisms collectively referred
to as the human microbiota. One of the main microbiota body sites is the female genital
tract, commonly dominated by Lactobacillus spp., in approximately 70% of women.
Each individual species can constitute approximately 99% of the ribotypes observed in
any individual woman. The most frequently isolated species are Lactobacillus crispatus,
Lactobacillus gasseri, Lactobacillus jensenii and Lactobacillus iners. Residing at the
port of entry of bacterial and viral pathogens, the vaginal Lactobacillus species can
create a barrier against pathogen invasion since mainly products of their metabolism
secreted in the cervicovaginal fluid can play an important role in the inhibition of bacterial
and viral infections. Therefore, a Lactobacillus-dominated microbiota appears to be a
good biomarker for a healthy vaginal ecosystem. This balance can be rapidly altered
during processes such asmenstruation, sexual activity, pregnancy and various infections.
An abnormal vaginal microbiota is characterized by an increased diversity of microbial
species, leading to a condition known as bacterial vaginosis. Information on the vaginal
microbiota can be gathered from the analysis of cervicovaginal fluid, by using the Nugent
scoring or the Amsel’s criteria, or at the molecular level by investigating the number and
type of Lactobacillus species. However, when translating this to the clinical setting, it
should be noted that the absence of a Lactobacillus-dominated microbiota does not
appear to directly imply a diseased condition or dysbiosis. Nevertheless, the widely
documented beneficial role of vaginal Lactobacillus species demonstrates the potential
of data on the composition and activity of lactobacilli as biomarkers for vaginal health.
The substantiation and further validation of such biomarkers will allow the design of better
targeted probiotic strategies.
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Introduction
Understanding the link between the microbiota and our health is the focus of a growing number of
research projects and papers, with new insights becoming available every day. The Human Micro-
biome Project and the European MetaHIT consortium initiated almost one decade ago, aim at
detailed characterization of the structure and the composition of the microbiota from various body
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sites. Primary attention has been focused on the composition
and function of the gastrointestinal (GI) microbiota and its rela-
tion with health and disease. Nevertheless, in recent years, the
microbiota from other body sites, such as the skin, oronasopha-
ryngeal cavity and genital tract, have also gained more attention.
An important body site providing a habitat for the development
of structured microbial communities is the vaginal tract, which
is broadly colonized by microorganisms known as the vagi-
nal microbiota (VMB). Residing at the port of entry of various
pathogens causing urogenital and sexually transmitted infections
(STIs) in women, there has been an increasing interest in the
composition and function of the VMB. Therefore, the VMB has
been recognized as an important factor involved in the protection
of the host from various bacterial, fungal and viral pathogens. In
addition, the VMB of the mother plays an essential role in the
initial colonization of new-born babies and therefore the devel-
opment of a healthy GI and skin microbiota (Dominguez-Bello
et al., 2010). It is recognized for a long time that the healthy VMB
(which generally refers to lack of symptoms, absence of various
infections, and good pregnancy outcome) is dominated mainly
by Lactobacillus species, of which the presence can be therefore
used as a valuable biomarker for evaluating health and disease.
However, it is only now since the more wide-spread applica-
tion of high throughput sequencing approaches possible to pro-
vide a balanced insight and perspective on their multifaceted
appearance in the VMB and their multifaceted role in vaginal
health.
Lactobacillus Species as Biomarkers for
Vaginal Health in Different Community
Groups of VMB
As mentioned above, lactobacilli are dominant species in
approximately 70% of women. Because of the limitations of
culture-based approaches, the detection and clustering of the
VMB in different groups is based in the last few years on culture-
independent methods, since culture-dependent methods have
some limitations. These molecular techniques include Sanger
sequencing of 16S rRNA of bacterial colonies (e.g., Verhelst
et al., 2005), terminal restriction fragment length polymorphism
(T-RFLP) of 16S rRNA (e.g., Zhou et al., 2010), qPCR (e.g., Jes-
pers et al., 2012; Datcu et al., 2013) and next generation sequenc-
ing (NGS) (Forney et al., 2010; Hummelen et al., 2010; Ravel et al.,
2011; Martin et al., 2012; Smith et al., 2012; Srinivasan et al., 2012;
Drell et al., 2013; Lee et al., 2013). Although different techniques
have been used, similar patterns have been observed inmost stud-
ies. For example, Verhelst et al. (2005) were one of the first to
categorize the VMB in a number of different grades or commu-
nity types based on Gram stain, the isolated dominant species, as
well as DNA sequencing of 16S rRNA genes. More specifically,
the authors reported the presence of four vaginal grades. Grade
I was characterized by a normal microbiota and has been sub-
sequently separated in grade Ia and Iab, in which L. crispatus is
the most dominant Lactobacillus species followed by L. jensenii,
and Ib, in which L. iners and L. gasseri are predominant. In
addition, the presence of a grade I-like VMB consists mainly
of Bifidobacterium spp. and some lactobacilli, mainly L. gasseri.
Grade II represents an intermediate status between grade I and
grade III, with the presence of L. iners, L. gasseri, L. crispatus,
Atopobium vaginae, Gardnerella vaginalis, Actinomyces neuii and
Peptoniphilus. Grade III is characterized by the presence of BV-
associated species (Prevotella bivia, A. vaginae, G. vaginalis, Bac-
teroides ureolyticus andMobiluncus curtisii) and low amounts of
Lactobacillus species, mainly L. iners. Finally, Grade IV is charac-
terized by the presence of a variety of Streptococcus spp. (Verhelst
et al., 2005). The results observed by Verhelst et al. were further
confirmed in Belgian women in follow up studies performed by
the same group (El Aila et al., 2009; Santiago et al., 2011).
Hummelen et al. (2010) reported, by using an Illumina-based
amplicon sequencing of the V6 region of the 16S rRNA gene,
on the presence of eight major clusters in Tanzanian women,
with only two of them associated with a normal microbiota
and dominated by L. crispatus and L. iners. The authors also
described the presence of four BV-associated clusters, dominated
by P. bivia, Lachnospiraceae, or a mixture of different species. The
remaining clusters were characterized as normal, intermediate or
BV-associated and were dominated mainly by G. vaginalis and
L. iners (Hummelen et al., 2010).
Using pyrosequencing of the V1–V2 hypervariable regions of
16S rRNA genes, Ravel et al. (2011) suggested that the VMB can
be divided in five major microbial communities based on sam-
ples from four ethnic groups—white, black, Hispanic and Asian
women in North America. According to the authors, micro-
bial communities belonging to group I (26.2%), II (6.3%), III
(34.1%), and V (5.3%) are dominated by L. crispatus, L. gasseri,
L. iners, and L. jensenii, respectively, and were isolated mainly
from white and Asian women (Figure 1), while group IV was
characterized by diverse species (see Non-Lactobacillus domi-
nated healthy VMB). Of interest, Smith et al. (2012) observed
that the cervical microbiota clusters in six distinct community
types of which clusters I–IV are similar to the vaginal com-
munity types reported by Ravel and co-workers. The authors
were able to detect two additional community types labeled as
VI and VII, but were not able to detect a L. jensenii domi-
nated microbiota, community type V as described by Ravel and
co-workers. Type VI was characterized by the presence ofG. vagi-
nalis, whereas type VII showed high, approximately even pro-
portions of G. vaginalis and Lactobacillus spp. An additional
cluster designated IIIb, was characterized by a predominance of
L. iners (Smith et al., 2012). Srinivasan et al. (2012) observed that
women without BV have vaginal bacterial communities domi-
nated either by L. crispatus or L. iners based on 16S rRNA gene
PCR and pyrosequencing. Other abundant lactobacilli in women
without BV in their study included L. jensenii and L. gasseri, while
five women without BV had different dominant bacteria includ-
ing A. vaginae, Leptotrichia amnionii, Prevotella amii, a first
phylogenetically-distinct group of DNA sequences representing
BV-associated bacteria (BVAB1) and Fusobacterium gonidiafor-
mans (Srinivasan et al., 2012). Therefore, the actual number of
vaginal community types is still under discussion and is driven
by the technology used, the sequencing depth, the number of
samples of each type, the computational choice made, as well
as the underlying data structures. However taken together, the
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FIGURE 1 | Composition of VMB during healthy and dysbiotic
states. The vaginal microbiota in healthy adult premenopausal women
can be divided into different community groups. The exact number and
type of community groups is still under debate (Verhelst et al., 2005;
Ravel et al., 2011; Gajer et al., 2012; Santiago et al., 2012). The most
commonly isolated dominating species belong to L. crispatus,
L. gasseri, L. iners and L. jensenii. The vaginal community group
dominated by L. iners is also often isolated during menstruation and in
the transitional microbiota between healthy and BV state or vice-versa.
Because this species is often isolated during BV, L. iners may not be
able to effectively protect against pathogens. Additionally, a
non-Lactobacillus dominated VMB is also documented in various healthy
individuals (Zhou et al., 2004; Ravel et al., 2011; Santiago et al., 2012).
For each compositional state, we have added an example of their
abundance based on the study of Ravel et al. (2011). However, these
numbers are only exemplary and should be considered with caution, as
they clearly depend on the study population (size and characteristics)
and they certainly need to be substantiated in further studies.
VMB appears to be mainly dominated by L. crispatus and L. iners,
while clusters dominated by L. jensenii and L. gasseri appear
less common (Figure 1). Of note, L. iners is present in almost
all women, including those with dysbiosis, while L. crispatus
is typically isolated from healthy women (see L. crispatus—
dominated microbiota and L. iners—harmful or beneficial for
vaginal health?). Furthermore, most studies also report clus-
ters without clear dominant species, but instead a proportion of
multiple Lactobacillus species. Other Lactobacillus species, such
as Lactobacillus rhamnosus (Pascual et al., 2008b), Lactobacillus
plantarum (Martin et al., 2008), Lactobacillus vaginalis (Srini-
vasan et al., 2012), Lactobacillus salivarius (Gustafsson et al.,
2011) and Lactobacillus coleohominis (Srinivasan et al., 2012) can
also be detected occasionally. A key challenge for future stud-
ies on the VMB composition is to integrate and further sub-
stantiate the findings of the studies using differing sequencing
approaches. Hopefully, this will result in the identification of clin-
ically relevant microbiota clusters that could be good biomark-
ers of the VMB state. This might be, as compared to the fecal
enterotypes (Siezen and Kleerebezem, 2011), more difficult than
initially anticipated given the fact that human microbial commu-
nities at different body sites appear in a continuum of different
compositions, as we will also highlight below for the VMB.
L. crispatus—Dominated Microbiota
According to the study of Ravel et al. (2011) mentioned above,
L. crispatus represents the dominant species of the vaginal bac-
terial community group I and is isolated mainly from white and
Asian women. L. crispatus and L. iners are also detected in group
IV that is not dominated by Lactobacillus species. The identifi-
cation of L. crispatus as the most frequently occurring species,
has also been reported in other populations such as Turkish,
Swedish, Mexican, Belgian, Japanese, American and Canadian
women (Kilic et al., 2001; Vasquez et al., 2002; Verhelst et al.,
2005; Ravel et al., 2011; Martinez-Pena et al., 2013; Chaban et al.,
2014). Frequent occurrence/dominance of this species has also
been reported in pregnant women based on a combined approach
of microbiological methods and genus-specific, multiplex and
species-specific PCR (Kiss et al., 2007). Apart from its occurrence
in the vagina, the species has been reported to be present in the
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rectum of healthy individuals and this colonization appears to be
associated with a decreased risk of BV (El Aila et al., 2009).
Recently, a comparative genome analysis of the most
abundant vaginal Lactobacillus species explored adaptation
mechanisms of vaginal lactobacilli in the vaginal ecosystem
(Mendes-Soares et al., 2014). L. crispatus has on average the
largest genome with the highest number of proteins unlike
the other vaginal strains studied. The L. crispatus strains were
found to have a unique DNA polymerase, bacteriocin and toxin-
antitoxin systems and genes encoding mobile genetic elements,
especially transposases that contribute to its large genome size.
Interestingly, lysogeny of phage particles was observed recently
in most of the vaginal isolates of L. crispatus, which could explain
the large number of genes encoding mobile genetic elements
(Damelin et al., 2011).
van de Wijgert et al. (2014) highlight in their systematic
review that longitudinal studies have indicated that a L. crispa-
tus-dominated VMB is more likely to transition to a L. iners-
dominated VMB and less likely to a dysbiotic state such as
BV and vice-versa. Another study showed that women with a
VMB dominated by L. crispatus have the lowest prevalence of
human immunodeficiency virus (HIV), herpes simplex virus type
2 (HSV-2) and human papillomavirus (HPV) (Borgdorff et al.,
2014). In addition, it has been reported that detection of L. crispa-
tus was associated with a 35% lower risk of HIV-1 RNA shedding
(Mitchell et al., 2013).
The presence of BV and loss of lactobacilli appears one of
the risk factors of preterm delivery (Donders et al., 2009). For
instance, 56% of women who delivered at term (n = 98)
were reported in another study to be colonized by two or more
species of lactobacilli which included L. crispatus (Petricevic et al.,
2014). The exact mechanisms by which lactobacilli could pre-
vent preterm delivery are not known, but pathogen inhibition
could be involved. For instance, Escherichia coli infection is a fre-
quent cause of preterm birth (Carey and Klebanoff, 2005) and
L. crispatus ATCC 33197 has been shown to contribute to the
inhibitory activity of vaginal secretions against E. coli (Ghartey
et al., 2014). The exact inhibitory compounds remain to be iden-
tified, but many clinical isolates of L. crispatus produce H2O2
in vitro, which has been proposed by Antonio et al. (1999) as
an important inhibitory factor against BV and other pathogens.
However, more recent studies show that H2O2 might not be
effective for maintaining vaginal health (O’Hanlon et al., 2010,
2011; Gong et al., 2014). For example, O’Hanlon et al. (2010) did
not observe any inhibitory activity of H2O2 against G. vaginalis,
P. bivia, Mycoplasma hominis, M. curtsii, Mobiluncus mulieris,
HSV-2, N. gonorrhoeae and Hemophilus ducreyii. The authors
also observed that in order to have efficient H2O2 production
in vitro, vigorous agitation to increase aeration is essential, which
has been supported by other authors as well (Strus et al., 2006;
Martin and Suarez, 2010). The low in vivo concentrations of
H2O2 could therefore be explained by the relatively hypoxic
environment of the vaginal lumen. Higher aeration and there-
fore production of H2O2 could possibly be achieved by sexual
intercourse, although cervicovaginal fluid and semen have been
shown to inactivate H2O2 (O’Hanlon et al., 2010; Gong et al.,
2014). In a follow up study, the authors observed that under
anaerobic growth conditions, physiological concentrations of lac-
tic acid (55–111mM) inactivated various BV-associated bacteria,
while physiological concentrations of H2O2 (<100µM) showed
no inactivation of the tested BV-associated bacteria, suggesting
that lactic acid might be significantly more protective against
infections in the vaginal environment in comparison to H2O2
(O’Hanlon et al., 2011). Moreover, at a concentration of 10mM,
H2O2 wasmore toxic to vaginal lactobacilli than to BV-associated
bacteria (O’Hanlon et al., 2011). Of note, H2O2 has been inves-
tigated for clinical treatment of BV. For example, Cardone et al.
(2003) showed that addition of 3% H2O2 for 1 week in the vagi-
nal niche could eliminate the symptoms of BV and facilitate
the restoration of a normal Lactobacillus dominated microbiota
(Cardone et al., 2003). However, another study using single vagi-
nal douching with 3% H2O2 failed to observe any positive results
as compared to the metronidazole control group (Chaithong-
wongwatthana et al., 2003), indicating that H2O2 is not a key
active metabolite of vaginal lactobacilli.
Therefore, the inhibition of E. coli and other BV-associated
bacteria by L. crispatus is probably a result of lactic acid pro-
duction or other not yet known factors. For example, Ravel
et al. (2011) observed that L. crispatus-dominated communities
have a lower vaginal pH as compared to communities domi-
nated by other species, suggesting that L. crispatus is one of the
highest producers of lactic acid, which is a key antimicrobial
product of lactobacilli. Witkin et al. (2013) found that D-lactic
acid, present in the highest amount in vaginal secretions of
L. crispatus-dominated women, can inhibit extracellular matrix
metalloproteinase inducer (EMMPRIN) production. EMMPRIN
induces matrix metalloproteinase 8 (MMP-8), which is suggested
to make the vaginal barrier more prone to upper genital infec-
tions linked to preterm birth. This might thus imply that D-lactic
acid production is an important factor in the protection against
preterm delivery. Moreover, L. crispatus can also have beneficial
effects via immunomodulation. For example, L. crispatus ATCC
33820 was shown to inhibit Candida albicans in vitro, via mod-
ulation of Toll-like receptors (TLR) 2/4, interleukin 8 (IL-8) and
human β-defensin 2 and 3 expression in epithelial cells (HeLa)
(Rizzo et al., 2013). Taken together, these studies clearly suggest
that the prevalence of L. crispatus in the VMB is an indicator of a
healthy vaginal microbial ecosystem.
L. iners—Harmful or Beneficial for Vaginal
Health?
L. iners is one of the most commonly observed vaginal species,
but was not commonly isolated since it is difficult to grow. It has
been reported from both healthy and BV-diagnosed women, in
contrast with L. crispatus which is mainly isolated from healthy
women. The species was discovered by Falsen et al. (1999) and
has escaped the attention of scientists for a long time, since it
grows only on blood agar, but not on MRS or Rogosa (Falsen
et al., 1999). L. iners has been detected in healthy Swedish
women (determined by Nugent score), Canadian (with a normal
Nugent score) (Burton and Reid, 2002), Nigerian (determined
by Nugent score) (Anukam et al., 2006c), Brazilian (determined
by Gram staining) (Martinez et al., 2008) and apparently healthy
Chinese women (Shi et al., 2009). Ravel et al. (2011) showed that
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microbial communities belonging to group III (34.1%) of healthy
white American and Asian women are dominated by L. iners as
described above. Srinivasan and co-workers also reported that
the VMB of 93% of American women without BV, as deter-
mined by Gram staining, are dominated by L. iners or L. crispatus
(Srinivasan et al., 2012). However, the authors also observed that
women with high levels of L. iners could be either BV positive or
negative, demonstrating that the presence of L. iners as dominant
Lactobacillus species might not be sufficient to protect against BV,
in contrast to the conditions in which other Lactobacillus species
dominate. Of note, other studies also detected L. iners during BV-
associated conditions using different analysis methods (Burton
and Reid, 2002; El Aila et al., 2009; Hummelen et al., 2010; San-
tiago et al., 2011). Interestingly, Witkin et al. (2013) showed that
L. iners-dominated women have lower concentrations of D-lactic
acid, suggesting that this could be one of the factors explaining
the prevalence of BV in these women. This was also corrobo-
rated by their in vitro studies and genome analysis of L. iners
which showed the incapability of the species to produce D-lactic
acid (Witkin et al., 2013). Furthermore, L. iners has often been
identified in the microbiota types intermediate between BV and
normal microbiota. For example, L. iners was found to be domi-
nant even after treatment of BVwithmetronidazole gel as studied
by Ferris et al. (2007), and further supported by Jakobsson and
Forsum (2007). The dominance of L. iners after treatment of BV
(Srinivasan et al., 2012; Shipitsyna et al., 2013) led to the sugges-
tion that L. iners might facilitate the transition between BV and
non-BV states. It has been reported that a L. iners dominant state
does not convert to a L. crispatus-dominated state even after BV
treatment (Lambert et al., 2013). Additionally, L. iners was found
to overgrow during menstruation, while the number of L. crispa-
tus decreased (Srinivasan et al., 2010, 2012; Gajer et al., 2012; San-
tiago et al., 2012). Furthermore, Petricevic et al. (2014) observed
that when L. iners was present alone without the presence of
any other Lactobacillus species in pregnant women (n = 27),
40.7% of these women delivered preterm. Although the authors
concluded on an association between solely L. iners presence in
healthy pregnant women and preterm delivery, these results are
not based on a well-controlled study population including 98
women who delivered at term and only 13 women who delivered
preterm, requiring further studies.
Taking all data above together, the current data thus suggest
that the presence of L. iners is not merely a biomarker reflect-
ing a healthy human VMB. Of interest, the strain L. iners AB-1
has an unusually small genome of∼1.3 Mbp single chromosome,
which seems to have undergone one or more rapid evolution
events resulting in massive gene loss and acquisition of genes
for optimal survival in the vaginal body site, such as iron-sulfur
genes (Macklaim et al., 2011). The strain’s genome encodes sev-
eral genes that allow it to respond adequately to rapid changes in
the environment, including CRISPR regions for phage resistance
and genes for glycogen utilization, and maltose and mannose
uptake. Interestingly, these genes appear to be over-expressed
only during BV and not under normal healthy conditions (Mack-
laim et al., 2013). Additionally, the small genome size of L. iners
may be indicative of a symbiotic or parasitic lifestyle in contrast
to other lactobacilli that show niche flexibility and genome sizes
of ca. 3 Mbp. Mendes-Soares et al. (2014) studied the genomes
of several L. iners strains and found that all the strains lack
several integral membrane proteins, protein families related to
the acetyltransferase GNAT (Gcn5-related N-acetyltransferases)
family and various transcriptional regulators present in other
vaginal strains whereas they possess numerous ABC transporter
permeases absent in other strains (Mendes-Soares et al., 2014).
L. iners strains encode for inerolysin, a cholesterol-dependent
pore-forming toxin, related to the vaginolysin virulence factor of
G. vaginalis (Rampersaud et al., 2011). Therefore, further stud-
ies are needed to determine the exact role of this interesting
species in vaginal health and disease and whether this strain is
merely a biomarker of a vaginal microbiota in transition or could
sometimes be a contributing factor to BV, as further discussed
below.
Non-Lactobacillus Dominated Healthy VMB
As mentioned above, recent studies also reported the pres-
ence of non-Lactobacillus dominated VMB in ca. 20–30% of
healthy women (Zhou et al., 2010; Ravel et al., 2011; Srini-
vasan et al., 2012). These kind of vaginal communities are
dominated by facultative or strict anaerobes, such as Gard-
nerella, Corynebacterium, Atopobium, Anaerococcus, Prevotella,
Peptoniphilus, Mobiluncus, Sneathia, Finegoldia, and Eggerthella.
Such diverse VMB appears to be typical for black and Hispanic
women (Ravel et al., 2011). It is still debated whether this type
of microbiota is thoroughly reflecting a healthy state or rather an
asymptomatic state of BV. Previous studies suggested that even
though this type of microbiota is non-lactobacilli dominated, the
abundant species are able to maintain the crucial protective func-
tion of the vaginal niche, i.e. a low vaginal pH by production
of lactic acid (Gajer et al., 2012). For example, members from
Atopobium, Streptococcus, Staphylococcus,Megasphaera, and Lep-
totrichia are capable of homolactic or heterolactic acid fermenta-
tion (Zhou et al., 2004). Therefore, in the absence of symptoms,
it appears that this type of diverse microbiota is normal and
healthy. Nevertheless, a close and regular monitoring of women
harboring a diverse type of VMB might be warranted to reduce
the risk of BV, STIs or other problems in apparently healthy
women, but who might have problems with fertility and preterm
delivery.
Temporal Shifts in the Composition of VMB
Most of the available studies on VMB are cross-sectional stud-
ies and thus only based on the collection of vaginal samples at
a single time point. Nevertheless, the vaginal communities can
change drastically over time based on changes in hormone levels,
antibiotic treatments, sexual activities and/or hygiene practices.
Therefore, a few recent prospective longitudinal studies exam-
ined the dynamics of the VMB, although mostly over a short
period of time. For instance, the number of L. iners appears
to remarkably increase during menses along with an increase
of G. vaginalis, while they subsequently decrease after menses
without intervention. Instead, the VMB dominated by L. crispa-
tus appears to remain stable during menses (Srinivasan et al.,
2010). The group of Vaneechoutte and co-workers reported that
menses immensely disturbs the diversity of the VMB (Santiago
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et al., 2012). They observed a 100-fold decline in L. crispatus
during menses, while the numbers of L. iners, G. vaginalis, A.
vaginae, and P. bivia drastically increased in women with a nor-
mal microbiota (Santiago et al., 2012). They even reported that
women with grade III VMB (diverse BV-associated state) had a
more stable VMB than women with normal (grade I) microbiota.
Gajer et al. (2012) also showed that the vaginal bacterial com-
munities of some women markedly change over time, switching
from one class to another, whereas others stay relatively sta-
ble. L. crispatus-dominated communities appear to often trans-
form to a community state III dominated by L. iners, or to IV-A
which is heterogeneous in composition and is characterized by
a modest proportion of L. crispatus, L. iners or other Lactobacil-
lus species as well as low numbers of strict anaerobic bacteria.
L. iners-dominated communities shift more often to community
type IV-B, which is dominated by a diverse number of bacte-
ria belonging mainly to the genus Atopobium, Prevotella, Parvi-
monas, Sneathia, Gardnerella, or Mobiluncus, but in rare cases
to IV-A. L. gasseri-dominated community groups rarely transit
to other types and stay stable over time. The fluctuation of vagi-
nal communities was affected by time in the menstruation cycle
and to a certain extent by sexual activity (Gajer et al., 2012).
Taken together, the studies of Srinivasan et al. (2010), Santiago
et al. (2012) and Gajer et al. (2012) established (i) an important
inter-individual variability in the VMB, (ii) a strong reduction
of L. crispatus and its replacement by L. iners or by Gram posi-
tive cocci during menstruation, and (iii) long term stability of the
VMB for only some women, which increases when L. crispatus
is the dominant species. However, other studies show a different
outcome. For instance, Chaban et al. (2014) did not observe any
significant changes in the VMB during specific menstrual phases
using cpn60-based analysis, although data of only 26 womenwere
analyzed in this study. Nevertheless, all these studies on tempo-
ral shifts are in agreement with one of the major conclusions of
the Human Microbiome Project that within-subject microbiota
variation over time is lower than between-subject variation for
all body sites, including the vagina (Human Microbiome Project
Consortium, 2012).
Lactobacillus Species Promote Vaginal
Health by Lowering the Risk of BV
As yet introduced, one of the most common vaginal disorders is
BV affecting fertile, premenopausal and pregnant women, result-
ing in millions of health care visits annually around the world.
BV is a complex, polymicrobial disorder characterized by the
disruption of the vaginal econiche, resulting in a reduction of
lactobacilli and an overgrowth of strict or facultative anaero-
bic bacteria such as Gardnerella spp., Atopobium spp., Prevotella
spp., Mobiluncus spp., as well as other taxa such as Clostridium
spp., Megasphaera spp., Leptotrichia spp., and Eggerthella-like
bacteria that were found even in pregnant women (Verstraelen
et al., 2004; Fredricks et al., 2005; Tamrakar et al., 2007). Despite
multiple attempts and focused research in the last decades to
determine the exact cause of BV, the evidence is still poor. Mul-
tiple factors are reported to be involved in the development of
BV, such as hormonal changes, the number of sexual partners,
smoking, personal hygiene and antibiotic treatment (Hellberg
et al., 2000; Verhelst et al., 2004; Brotman et al., 2008, 2014a).
In recent years, culture-independent techniques based on the
analysis of 16S rRNA gene sequences as described above have
identified 3 phylogenetically-distinct DNA sequences represent-
ing potentially BV-associated bacteria (BVAB) BVAB1, BVAB2,
and BVAB3, which are distantly related to the species of the phyla
Actinobacteria and Firmicutes. BVABs, more specifically BVAB2,
together with Megasphaera, Leptotrichia, and Eggerthella-like
bacteria were found to be more representative species of BV than
Gardnerella and Atopobium (Fredricks et al., 2005). Fluorescent
in-situ hybridization (FISH) analysis by Swidsinski and cowork-
ers revealed the presence of a dense polymicrobial biofilm on the
vaginal epithelial surface in biopsies of women with BV. This
biofilm is assumed to be initiated by G. vaginalis strains, which
then becomes a scaffold for other species to adhere (Swidsinski
et al., 2010; Verstraelen and Swidsinski, 2013). It is still uncertain
whether these species are actually involved in the development of
BV and therefore can be considered as pathogens, or if they are
opportunistic organisms which are well adapted to the changes in
the vaginal environment, as described for L. iners (see L. iners—
harmful or beneficial for vaginal health?). When symptomatic,
BV is characterized by vaginal discomfort and homogeneousmal-
odorous vaginal discharge. Twomethods are used for diagnosis of
BV: the Amsel criteria and the Nugent scoring system. The Amsel
criteria are often used in clinical practice (Amsel et al., 1983) and
require the presence of at least three of the following criteria to
diagnose BV: (i) thin, homogeneous vaginal discharge; (ii) vagi-
nal pH higher than 4.5; (iii) “fishy” odor of vaginal fluid before or
after addition of 10% potassium hydroxide (KOH) (whiff test);
(iv) presence of clue cells on microscopic evaluation of saline
wet preparations. However, the use of Amsel criteria is debatable,
especially during pregnancy, when increased vaginal discharge is
observed (Guise et al., 2001). There is not a major difference in
the prevalence of vaginal discharge and odor among women with
or without BV, which together with the fact that women often do
not report any vaginal discharge, wetness, or odor makes the cri-
teria subjective (Klebanoff et al., 2004). In addition, the pH value
of the samples depends on how and where the samples are exactly
taken. Secondly, the Nugent score is based on the Gram staining
of vaginal smears and includes the microscopic quantitation of
bacterial morphotypes yielding a score between 0 and 10 (Nugent
et al., 1991). A score of 0–3 is normal, 4–6 is intermediate, and
7–10 is considered as BV. Important to mention is that around
50% of all women with BV as determined by Nugent score are
asymptomatic. It is still unclear whether these women are asymp-
tomatic or the symptoms are insignificantly pronounced and
therefore poorly recognized and under-reported. These asymp-
tomatic and most of the time non-inflammatory BV conditions
can have important clinical consequences. For example, it has
been reported that changes in the VMB are associated with var-
ious vaginal and urinary tract infections (Harmanli et al., 2000;
Koumans et al., 2002). Furthermore, BV may result in increased
rates of early pregnancy loss and preterm delivery (Eckert et al.,
2003; Verstraelen et al., 2005). It has also been shown that
BV facilitates the acquisition of sexually transmitted infections
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such as Neisseria gonorrhoeae, Chlamydia trachomatis, HIV and
HSV-2 (Martin et al., 1999; Cherpes et al., 2003b; Wiesenfeld
et al., 2003). Moreover, genital tract shedding of HIV, HSV-2
(Cherpes et al., 2005) and cytomegalovirus (Ross et al., 2005)
is significantly higher in women with BV compared to BV-free
women.
Several mechanisms have been proposed to explain how BV
could increase the risk of STIs acquisition. First, the loss of pro-
tective Lactobacillus species and other changes in the vagina,
such as elevated pH and decreased lactic acid concentrations,
related to BV could facilitate the survival of vaginal pathogens.
Secondly, BV-related microorganisms produce mucin-degrading
enzymes in the vaginal fluid (e.g., sialidases), which degrade the
mucus coating the vaginal and cervical epithelium, considered
as one of the major components of the barrier against infec-
tion. Macklaim et al. (2013) also reported that the metabolome
during BV conditions differs from the healthy stage. For exam-
ple, the BV samples were enriched of enzymes, which belong
mainly to P. amnii and some to G. vaginalis, used for the
metabolism of glycans and more precisely of glycogen. The over-
expression of those enzymes results in the production of suc-
cinate and short-chain fatty-acids, while healthy conditions are
characterized by a high level of lactic acid. This mucus and
glycogen degradation may cause micro-abrasions or epithelial
cell alterations which could facilitate binding of pathogens to
the underlying epithelial cell receptors. Finally, the immuno-
logical balance in the vaginal tract appears to be changed dur-
ing BV with increased levels of pro-inflammatory cytokines
which could render women more susceptible to the acquisi-
tion of STIs (Brotman, 2011; Gillet et al., 2011; Nardis et al.,
2013).
Taken together, different studies on BV show different out-
comes, which can be partially explained by the different diag-
nostic criteria used (e.g., Nugent score vs. Amsel criteria). There
exists thus a clear need to complement these methods with
culture-dependent and NGS methods to better diagnose BV and
characterize the VMB.
Lactobacillus Species Promote Vaginal
Health by Lowering the Risk of STIs
STIs can be caused by over 30 bacterial, viral and parasitic
pathogens known to be transmitted sexually, including vaginal,
anal and oral sex. Important pathogens with a high incidence
include bacterial pathogens such as C. trachomatis,N. gonorrhoea
and viral pathogens such as HIV, HSV-2 and HPV. Since these
infections have a considerable impact on reproductive and gen-
eral health, STIs belong to the top five disease categories for which
adults seek medical attention. Moreover, the majority of STIs
remain asymptomatic which implies increased transmission risks
of STIs. As described above, Lactobacillus species are thought to
be a valuable biomarker for vaginal health supported by the fact
that the presence of BV increases the risk of STIs acquisition.
Therefore, a better understanding of the relationship between
the vaginal microbiome and risk of STIs combined with refined
biomarkers for a healthy VMB may lead to new strategies aiming
at maintaining and/or restoring more protective vaginal bacterial
communities.
Bacterial STIs and the VMB
C. trachomatis infection is one of the most common bacterial
STIs worldwide, with an estimated number of 105.7 million new
infections annually in 2008. Untreated chlamydia may lead to
pelvic inflammatory disease, tubal infertility and ectopic preg-
nancy. BV was found to be a strong predictor of C. trachoma-
tis and N. gonorrhoeae infection among women with recent
exposure to a male partner with chlamydial or gonococcal ure-
thritis (Wiesenfeld et al., 2003). Another longitudinal study iden-
tified a significant association between intermediate/high Nugent
score and increased risk of incident trichomonal, gonococcal and
chlamydial infection (Brotman et al., 2010). Furthermore, lon-
gitudinal, randomized study observed that metronidazole treat-
ment of BV-positive women for 1 year had significantly lower
incidences of Chlamydia, however no appropriate placebo con-
trol was used (Schwebke and Desmond, 2007). Multiple studies
thus suggest that BV increases the risk of incident C. trachoma-
tis infection. Interestingly, combined 16S rRNA sequencing and
metagenomics on vaginal samples of 101 C. trachomatis-infected
women (92% African-American) treated at diagnosis revealed
low proportions of Lactobacillus or specific L. iners genome types
as a hallmark of the chlamydia infected state (Ma et al., 2013a).
N. gonorrhoeae is the second most common bacterial STIs
affecting around 36.4 million adults worldwide in 2008. This
Gram-negative bacterium causes infections of the female cervix,
but also of the vagina, pharynx and rectum (Vielfort et al.,
2008). As described above, multiple studies describe associations
between BV and N. gonorrhoea infection. Given that the ini-
tial interaction between N. gonorrhoeae and the epithelial cells
of the host is critical for successful colonization of the mucosa
(Vielfort et al., 2008), several in vitro studies focused on the
ability of vaginal lactobacilli to inhibit gonococcal adherence to
epithelial cells. For example, it has been shown that L. jensenii
ATCC 25258 could both reduce adhesion and invasion ofN. gon-
orrhoeae, whereas L. gasseri ATCC 33323 could displace adher-
ent N. gonorrhoeae (Spurbeck and Arvidson, 2008). A follow
up study determined that released surface components (RSC)
of L. jensenii ATCC 25258 are able to inhibit N. gonorrhoeae
interaction with endometrial epithelial cells in vitro by occlud-
ing fibronectin binding sites. Future experiments are required to
verify whether the surface-located enolase protein, identified as
the main gonococcal adherence inhibiting factor of the RSC, is
indeed the fibronectin-binding protein (Spurbeck and Arvidson,
2010). Nevertheless, future in vivo studies need to validate the
importance of adherence competition in pathogen inhibition, in
addition to more direct antimicrobial mechanisms of lactobacilli
(see further).
Viral STIs and the VMB
HIV infections remain one of the major global public health
issues to date, accompanied by an estimated direct total lifetime
medical cost of 12.6 billion dollars in the US in 2008 (Owusu-
Edusei et al., 2013). By the end of 2013, approximately 35 million
people were living with HIV and this number is increasing by
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around 2.1 million new infections each year. In order to increase
the possibility for new therapies, a better understanding of the
interplay between the VMB and HIV infections could be of cru-
cial importance. A significant association was detected between
women with BV, and thus lack of predominant Lactobacillus spp.,
and increased susceptibility to HIV acquisition (Atashili et al.,
2008; Low et al., 2011). Furthermore, the prevalence and inci-
dence of HSV-2 infections as well as the incidence of N. gonor-
rhoeae infections appear to be independent risk factors for HIV
acquisition (van deWijgert et al., 2009). Possible mechanisms for
this relationship include (i) activation of immune response and
inflammation during BV, (ii) disruption of the vaginal epithelium
through which HIV could reach its target immune cells, and (iii)
decreased Lactobacillus spp. causing elevated pH and lowered
H2O2 concentrations (Petrova et al., 2013). Furthermore, BV is
also often detected inHIV-seropositive women (Spear et al., 2011;
Borgdorff et al., 2014). HIV-positive women with BV are charac-
terized by a higher bacterial diversity compared to HIV-negative
women with BV (Spear et al., 2008). Other studies also detected
an association between BV and increased viral replication and
HIV shedding suggesting that BV may have a role in enhanc-
ing HIV infectivity (Sha et al., 2005; Coleman et al., 2007; Tanton
et al., 2011). Of note the presence of G. vaginalis, M. hominis,
and P. biviawas also related to increased HIV expression whereas
L. acidophilus was not (Hashemi et al., 2000). In addition, BV
has been also associated with increased rates of transmission of
HIV from infected women to their male partners, which suggests
that BV could be responsible for new HIV-1 infections in Africa
(Cohen et al., 2012). More detailed information on the antiviral
mechanisms are discussed elsewhere (Petrova et al., 2013).
HSV-2, the main cause of genital herpes disease, is affecting
around 20% of the female worldwide population in 2008 aged
between 15 and 49 years (Looker et al., 2008). In order to better
understand the relationship between the VMB and HSV-2 infec-
tions, multiple studies focused on the association between BV and
HSV-2. Of note, the relationship between BV and HSV-2 is found
to be potentially bidirectional. Several studies, some with longi-
tudinal and some with cross-sectional study design, identified BV
and the lack of Lactobacillus-predominant microbiota as an inde-
pendent risk factor of HSV-2 acquisition (Cherpes et al., 2003a,b;
Gottlieb et al., 2004; Kaul et al., 2007; Gallo et al., 2008). More-
over, a longitudinal study performed in the US described BV as
a risk factor for HSV-2 replication and genital tract shedding,
which can enhance the spread of HSV-2 (Cherpes et al., 2005).
Evidence was also found that BV prevalence is higher after HSV-2
seroconversion in a female African population (Kaul et al., 2007;
Nagot et al., 2007; Masese et al., 2014), for which Masese and
colleagues described that incident HSV-2 was associated with a
30% increase in odds of episodes of BV. This association was also
identified within female US populations (Allsworth et al., 2008;
Cherpes et al., 2008). More specifically, positive HSV-2 serol-
ogy is a risk factor for acquisition or subsequent episodes of BV
(Cherpes et al., 2008; Masese et al., 2014). Prevalent HSV-2 infec-
tion was also associated with increased incidence of Trichomonas
vaginalis and N. gonorrhoeae (Kaul et al., 2007). Of note, all stud-
ies mentioned above diagnosed BV byNugent scoring andHSV-2
by PCR or serology testing. HSV-2 infection can also increase
the rate of HIV-1 acquisition (Minton, 2013). To date, direct and
indirect mechanisms could be responsible, with co-infection of
cells by HIV and HSV-2 as a potential direct mechanism, which
appeared unlikely based on infection results of an ex vivo skin
explant model (Minton, 2013). Indirect mechanisms include dis-
ruption of epithelial barriers by HSV-2 and further inflamma-
tion, resulting in the recruitment of T lymphocytes and therefore
increased episodes of HIV (Zhu et al., 2009). Furthermore, HSV-
2 has also been shown to induce expression of an antimicrobial
peptide LL-37 by keratinocytes, which is able to increase the sus-
ceptibility of Langerhans cells to HIV-1 due to increased expres-
sion levels of HIV coreceptors CD4 and CCR5 (Ogawa et al.,
2013). Therefore, strategies to inhibit HSV-2 infection may also
benefit indirect prevention of HIV-1 infections.
A third class of viral STIs which should not be underestimated
consists of HPV infections. There are more than 100 types of
HPV of which 13 are identified as high risk HPV types able to
cause cervical cancer. Multiple studies have identified a positive
association between BV and cervical HPV infection, supported
by the overall estimated odds ratio of ameta-analysis including 12
eligible studies investigating the BV-HPV association (Gillet et al.,
2011). BV was associated with the acquisition or reactivation of
HPV infection, whereas no association was found with HPV per-
sistence or the development of squamous intraepithelial lesions
(SIL) (Watts et al., 2005). However, others observed a decreased
or slower clearance of HPV lesions in women diagnosed with BV
(Guo et al., 2012; Brotman et al., 2014b). More detailed molecular
studies indicated that HPV infection seems to be associated with
changes in the composition of the VMB, namely with a decrease
in lactobacilli and increase in microbiota diversity (Clarke et al.,
2012; Dols et al., 2012; Gao et al., 2013; Lee et al., 2013). These
data are supported by the fact that a vaginal pH above 5 resulted
in a 10–20% increased HPV risk and is associated with low-grade
SIL diagnosis, as identified in premenopausal women from Costa
Rica (Clarke et al., 2012). During HPV infection, L. crispatus
was less frequently and L. gasseri and G. vaginalis were more
frequently isolated from vaginal samples (Dols et al., 2012; Gao
et al., 2013). A close study of a Korean twin cohort revealed an
association between HPV and the abundance of Fusobacteria. In
particular, Sneathia spp. were identified as potential microbiolog-
ical markers of HPV infection, although the specificity for HPV
should be further verified (Lee et al., 2013). Recently, a significant
association between microbiota community types, as described
by Gajer et al. (2012) using the same vaginal samples, and remis-
sion of HPV infection was observed. Apart from clusters III and
IV having a greater proportion of HPV infections compared to
other clusters, group IV-A increased the risk for transition to
a HPV-positive state and group IV-B showed the slowest HPV
clearance rate (Brotman et al., 2014b). In general, microbiota
dominated by L. iners or lacking sufficient numbers of lactobacilli
may represent microenvironments with increased risk of HPV
acquisition/persistence (Brotman et al., 2014b). Taken together,
reduced Lactobacillus counts are associated with HPV infection.
Therefore, the rational selection of Lactobacillus probiotics with
potential impact on HPV risk may represent a valuable strat-
egy to lower HPV incidences/persistence. In a first longitudinal
pilot study, 54 HPV-positive and low-grade SIL-positive women
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consumed a probiotic drink containing L. casei Shirota every day
for 6 months. Probiotic users were twice as likely to have cervi-
cal lesion clearance, although no change in HPV detection was
observed (Verhoeven et al., 2013). Further research is required to
determine if probiotic interventions are able to reduce produc-
tive and/or recurrent HPV infections, as well as other viral STIs,
since the current evidence is very limited.
Finally, we want to highlight the importance of well-designed
clinical studies, which should include a statistically significant
number of well-characterized women sampled longitudinally and
which should control for potential confounding factors such as
sociodemographic/economic, (sexual) behavioral and microbio-
logical factors in order to define the exact role of the VMB in STIs,
as well as to define the exact VMB communities. Primarily, atten-
tion should be given to the design of clinical studies examining
associations between STIs and potential risk factors, which can
be longitudinal or cross-sectional. Longitudinal studies, analyz-
ing multiple samples per individual taken at follow up visits have
the advantage to provide information on a causal relationship
and possible fluctuations in STI episodes or VMB composition.
Cross-sectional studies, analyzing only one sample per individ-
ual can only suggest association and should be taken within a
representative time frame (e.g., not within menses, active/passive
HSV-2 infection, etc.). Secondly, clinical data obtained should
be adjusted for potential confounding factors of which impor-
tant ones are age, race, sexual activity, condom use, number of
sexual partners, time of menstruation, use of antibiotics, hor-
monal contraception, vaginal douching and BV/STI prevalence
and episodes. For instance, it has been recently reported that use
of condoms is associated with L. crispatus colonization of the
vagina, which has also been shown to be protective against BV
(as well as other STIs) (Ma et al., 2013b), indicating that it is an
important confounding factor.
How Vaginal Lactobacilli Exert Their Health
Promoting Effects
Since lactobacilli appear to be a hallmark of a healthy vaginal
ecosystem, it is important to understand how they can exert
important health-promoting effects, because knowledge on the
exact molecular mediators can also promote the discovery and
implementation of biomarkers. Postulated direct and indirect
anti-pathogenic mechanisms of lactobacilli include (i) produc-
tion of lactic acid and bacteriocins that directly kill or inhibit
bacterial and viral pathogens, (ii) formation ofmicrocolonies that
adhere to the epithelial cell receptors and form a physical barrier
against pathogen adhesion (Petrova et al., 2013), and (iii) stimula-
tion of host defense mechanisms against pathogens (Lebeer et al.,
2010). Yet again, although the health benefits of vaginal lacto-
bacilli are widely recognized, they have been poorly substantiated
by molecular studies.
Production of Lactic Acid and Bacteriocins
Directly linked to the presence of lactobacilli, the production of
lactic acid is accepted as a hallmark beneficial activity of the VMB.
Lactic acid has been linked to pathogen exclusion and their con-
centrations could also be seen as important biomarkers of vaginal
health, although the current evidence is still mainly based on in
vitro studies. For example, it has been shown that lactic acid is
able to inactivate a wide range of reproductive tract pathogens,
including the uropathogenic E. coli (Juarez Tomas et al., 2003),N.
gonorrhoeae (Graver andWade, 2011), and C. trachomatis (Gong
et al., 2014). However, for the latter, similar inactivation was iden-
tified for formic acid and acetic acid, suggesting that sufficient
hydrogen ions are involved in the mechanism to kill Chlamydia
(Gong et al., 2014). Furthermore, a strong pH-independent inhi-
bition of C. trachomatis by L. brevis CD2 (DSM 11988) could also
be observed during early steps of infection. The same strain was
also able to inhibit HSV-2-induced Chlamydia persistence (Mas-
tromarino et al., 2014). Lactic acid has also been shown to play
an important role in direct inactivation of HSV-2 (Conti et al.,
2009) and HIV-1, due to effective capturing by acid cervicovagi-
nal human mucus (Lai et al., 2009; Shukair et al., 2013). Given
these data, lactic acid has been investigated for clinical treatment
of BV. For example, re-establishment of the normal Lactobacil-
lus dominated microbiota after the use of lactic acid gels has
been reported for both pregnant and non-pregnant women after
a few days of treatment (Andersch et al., 1986; Holst and Brand-
berg, 1990). However, another study failed to observe any positive
results (Boeke et al., 1993), suggesting that well-designed clinical
studies are required in order to investigate the possibility of using
lactic acid as an alternative BV treatment.
Bacteriocins represent another main mechanism of direct
inhibition of pathogens. Bacteriocins are known as ribosoma-
lly synthesized antimicrobial peptides and proteins with activ-
ity against closely related microorganisms (Cotter et al., 2013),
although, as recently reported, several bacteriocins have a wide
activity against unrelated microorganisms and viruses. For exam-
ple, it has been shown that L23 bacteriocin (7 kDa) produced
by Lactobacillus fermentum L23 displays a wide inhibitory activ-
ity against Gram-negative and Gram-positive pathogenic strains
and Candida spp. (Pascual et al., 2008a). Fermenticin HV6b
(class IIa antimicrobial peptide), produced by L. fermentum
HV6b MTCC 10770, shows growth inhibition of G. vaginalis,
Mobiluncus, staphylococci and streptococci (Kaur et al., 2013). In
another study, Donia et al. (2014) were able to purify and reveal
the structure of a thiopeptide antibiotic, named lactocillin, pro-
duced by reference strain L. gasseri JV-V03. Lactocillin has been
shown to possess activity against S. aureus, Enterococcus faecalis,
G. vaginalis, and Corynebacterium aurimucosum (Donia et al.,
2014).
Adhesion
Adherence of vaginal lactobacilli to host cells has been shown
to prevent colonization by pathogenic microorganisms in vitro
(Osset et al., 2001; Atassi et al., 2006) and in vivo (Anukam et al.,
2006b). Hereby, the adherence pattern of lactobacilli appears to
be more loose than that of (BV) pathogens that occur in thicker
biofilms (Machado et al., 2013). Various cell surface compo-
nents (proteins/glycoproteins, exopolysaccharides) of GI lacto-
bacilli have been shown to play a role in bacterial adhesion to
the host/pathogens (Lebeer et al., 2010). However, information
on adhesins in vaginal Lactobacillus strains is lagging behind.
Several vaginal Lactobacillus isolates have been shown to block
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the adhesion of vaginal pathogens to vaginal epithelial cells in
vitro, such as by displacement and competition. For example,
displacement of G. vaginalis by various lactobacilli has been
reported (Mastromarino et al., 2002). Furthermore, exclusion
and competition of S. aureus, Group B streptococci (Zarate and
Nader-Macias, 2006), Pseudomonas aeruginosa, Klebsiella pneu-
monia, and E. coli (Osset et al., 2001), uropathogenic E. coli
(UPEC), G. vaginalis and P. bivia (Atassi et al., 2006), and of
T. vaginalis (Phukan et al., 2013) by Lactobacillus species have
also been observed. An in vitro anti-HSV-2 activity of vaginal
L. brevis, L. plantarum, and L. salivarius isolates was shown to
be directly dependent on the adhesiveness of each bacterial strain
to human epithelial cells (Mastromarino et al., 2002, 2011).
Interestingly, the genomes of the recently sequenced vagi-
nal lactobacilli have been shown to encode various adhesins
that could have a role in pathogen exclusion. For instance, the
genome of L. pentosusKCA1 codes for large-sizedmucus-binding
and fibrinogen-binding proteins (FbpA) (Anukam et al., 2013).
Recently, we were able to show that the genome of L. plantarum
CMPG5300 contains many putative adhesion proteins, includ-
ing predicted collagen-binding, mucus-binding, chitin-binding,
fibrinogen-binding and mannose-binding proteins (Malik et al.,
2014). The binding of L. iners AB-1 to fibrinogen has been sug-
gested to be associated with the involvement of its genome-
encoded fibrinogen-binding protein (McMillan et al., 2013),
although this remains to be further validated, for example, by
mutational analysis. A comparative genomic approach highlights
that the strong adhesive capacity of L. crispatus and some unique
adhesins play a key role in competitive exclusion of important
BV pathogens such as Gardnerella vaginalis (Ojala et al., 2014).
Although the exact role of specific adhesins in the adhesion of
vaginal Lactobacillus species to host cells remains to be further
explored, it becomes apparent that (loose) adherence of lacto-
bacilli could be a biomarker of vaginal health. The rapid detection
of specific Lactobacillus spp., such as L. crispatus detection in the
human vagina by FISH approaches (Machado et al., 2013), could
thus hold promise as novel molecular biomarkers of vaginal
health.
Stimulation of Host Defense Mechanisms
Finally, lactobacilli probably also promote health in the vagi-
nal ecosystem via various immunomodulation mechanisms,
although this role is still poorly understood and mainly based on
in vitro work. For example, Rose et al. (2012) reported that when
the vaginal epithelial cells (VEC) were subjected to TLR agonists,
L. crispatus ATCC 38820 and L. jensenii ATCC 25258 were able
to temper the immune response. Furthermore, cytokine profiles
of VEC were not affected after colonization with these commen-
sal vaginal strains. However, the anti-inflammatory effect of the
lactobacilli differed amongst agonists and strains, indicating that
the immune-modulating effect of commensal strains depends on
specific molecular interactions (Rose et al., 2012). This species-
specific modulation of the host’s immune response by the VMB
was also inferred by Doerflinger et al. (2014), who discovered
that L. crispatus ATCC 38820 does not significantly up-regulate
pattern-recognition receptor (PRR) signaling pathways in human
primary vaginal epithelial cells (V19), whereas L. iners ATCC
5195 does. Further, only the studied L. iners strain was shown
to increase the expression of TNF at RNA level, although an
increased secretion of TNF on protein level was not observed
(Doerflinger et al., 2014). Whether L. iners is contributing to
vaginal health is therefore still controversial. Wagner and John-
son (2012) investigated the influence of L. rhamnosus GR-1 and
L. reuteri RC-14 on the inflammatory response of VK2/E6E7
to C. albicans and observed that the probiotic strains modulate
the VK2/E6E7 inflammatory immune response to C. albicans by
suppressing the expression of induced NF-κB inhibitor kinase
alpha (Iκκα), TLR2, TLR6, IL-8, and TNF, suggesting that they
inhibit NF-κB signaling (Wagner and Johnson, 2012). The effect
of L. rhamnosus GR-1 and L. reuteri RC-14 on the host’s immune
system was also investigated in vivo (Bisanz et al., 2014). After
treatment with these strains, significantly increased levels of IL-5
(as determined by cytokine ELISA assay) and IL-18 (as deter-
mined with microarray) could be detected in vaginal swabs, but
not for IL-1β, TNF, IL-6, and GM-CSF. Furthermore, expres-
sion of complement receptors 1 and 3a and TLR2 was signifi-
cantly increased, suggesting that the lactobacilli have instigated
the innate immune system (Bisanz et al., 2014). Nevertheless,
more research is needed to substantiate the expression of specific
cytokines and immune factors as potential biomarkers of vaginal
health.
Probiotics—Exogenously Administered
Lactobacillus Strains to Restore Vaginal
Health
Since a healthy VMB is mainly dominated by Lactobacil-
lus species, the perspective of using exogenously applied
Lactobacillus probiotics to restore and/or maintain vaginal health
becomes feasible. Probiotics are “live microorganisms that, when
administered in adequate amounts, confer a health benefit on
the host” (FAO/WHO, 2001). Various studies have yet been per-
formed in order to investigate the role of single or a combination
of probiotics for the treatment of BV as themost common vaginal
disorder (Table 1) (the main focus of this review). Furthermore,
several studies also showed the potential of exogenously admin-
istered probiotics for the treatment of another common vaginal
disorder, namely candidiasis (Ehrstrom et al., 2010; Vicariotto
et al., 2012; De et al., 2014).
Treatment of BV Using Only Probiotic Therapy
One of the first studies to use probiotic strains for the treatment
of BV was conducted in 1992 (Hallen et al., 1992). The authors
used vaginal capsules containing 108–109 CFU of a H2O2 pro-
ducing L. acidophilus (Vivag R©, Pharma-Vinci A/S, Denmark)
but did not observe any efficacy for the treatment of BV (as
assessed by the Amsel criteria). Nevertheless, it is important to
note that 50% of the patients in the probiotic group and 86%
of the placebo group did not complete the trial, which makes
it difficult to evaluate the efficacy of the study. In comparison,
by using a H2O2 producing L. acidophilus, Parent et al. (1996)
observed a high BV cure rate of 88% after 4 weeks of treatment.
The authors conducted a placebo-controlled study that included
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TABLE 1 | Use of probiotic strains for the treatment of BV.
Type of intervention and probiotics used BV cure rate Type of study;
Duration;
Size
References
TREATMENT OF BV ONLY WITH PROBIOTICS
Vaginal capsules containing 108 to 109 CFU* L. acidophilus or
placebo for a period of 6 days
21% cure rate compared to 0% in the
control group
R, DB, PC**;
20–40 days;
57 women
Hallen et al., 1992
Vaginal capsules introduced 1–2 times daily containing at least
107 L. acidophilus and 0.03mg estradiol for 6 days
88% cure rate compared to 22% in
the control group
R, PC;
4 weeks;
32 women
Parent et al., 1996
Daily vaginal capsules containing 109 CFU L. rhamnosus GR-1
and 109 CFU L. reuteri RC-14 or twice a day 0.75%
metronidazole gel for 5 days
65% cure rate compared to 33% in
the metronidazole treated group
E, OB, AC;
30 days;
40 women
Anukam et al.,
2006b
Vaginally introduced 1–2 capsules daily containing at least 109
CFU of L. brevis CD2, L. salivarius FV2 and L. plantarum FV9 for a
period of 7 days
50% cure rate compared to 6% in the
control group
R, DB, PC;
3 weeks;
34 women
Mastromarino et al.,
2009
TREATMENT OF BV WITH PROBIOTICS IN COMBINATION WITH ANTIBIOTIC THERAPY
Vaginally introduced 100mg clindamycin ovules for 3 days,
subsequently tampons containing 108 CFU of L. gasseri, L. casei
rhamnosus, L. fermentum or placebo tampons during the next
menstrual period
As defined by Amsel’s criteria 56%
cure rate in the probiotic group and
62%, in the control group; As defined
by Nugent’s score 55% cure rate in
the probiotic group and 63%, cure in
the control group
R, DB, PC;
Two menstrual periods;
187 women
Eriksson et al., 2005
Oral intake of 500mg metronidazole for 7 days and oral probiotic
capsules containing L. rhamnosus GR-1 and L. reuteri RC-14
each 109 CFU or placebo for 30 days starting on day 1 of the
metronidazole treatment
88% cure rate compared to 40% in
the control group
R, DB, PC;
30 days;
125 women
Anukam et al.,
2006a
Oral intake of 300mg clindamycin for 7 days, followed by vaginal
capsules containing 109 CFU L. casei rhamnosus for 7 days
83% cure rate compared to 35% in
the control group
R, OB, PC;
4 weeks;
190 women
Petricevic and Witt,
2008
Vaginal cream containing 2% clindamycin followed by vaginal
capsules containing 108–109 CFU L. gasseri Lba EB01-DSM
14869 and 108–109 L. rhamnosus Lbp PB01-DSM 14870. The
probiotic treatment was performed and subsequently repeated for
10 days after each menstruation during 3 menstrual cycles
65% cure rate compared to 46% in
the control group
R, DB, PC;
6 menstrual periods;
100 women
Larsson et al., 2008
Treatment with a single dose of tinidazole (2 g) plus either 2 oral
capsules of L. rhamnosus GR-1 and L. reuteri RC-14 or placebo
daily in the morning for 28 days, starting on the first day
The probiotic group had a significantly
higher cure rate of BV (87.5%) than
the placebo group (50.0%)
R, DB, PC;
28 days;
64 women
Martinez et al., 2009
Oral 500mg of metronidazole followed by vaginal application once
a week for 6 months of a capsule containing 40mg of L.
rhamnosus (N40000 CFU) beginning 8 days after the
metronidazole therapy
During the first 6 months of follow-up,
96% of patients in the probiotic group
had a balanced vaginal ecosystem.
Follow-up over 12 months showed
reduced recurrence of BV in the
probiotic group
R, NB;
6 months;
46 women
Marcone et al., 2010
Oral intake of 400mg metronidazole for period of 7 days followed
by vaginal pessary containing L. acidophilus KS400 of 107 CFU
and 0.03mg estriol for 12 days
72% cure rate compared to 73% in
the control group
R, DB, PC;
6 months;
268 women
Bradshaw et al.,
2012
*CFU, colony forming units.
**R, randomized; DB, double blind; NB, not blind; PC, placebo controlled; OB, observer blind; AC, active controlled.
both pregnant and non-pregnant women who were treated with
a pharmaceutical product Gynoflor containing at least 107 CFU
L. acidophilus and 0.03mg/ml estradiol (Parent et al., 1996).
Both studies described above do not use well-characterized pro-
biotic Lactobacillus strains. Even the species designation of these
strains could be incorrect, since the group of L. acidophilus has
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been shown to be highly diverse (Falsen et al., 1999). The exact
characterization of the probiotic strains used as well as their
detailed molecular characterization is mandatory when conduct-
ing clinical trials and subsequently delivering a probiotic prod-
uct to the market. The European Food Safety Authority (EFSA)
has stated that an important step toward the approval of health
claims for probiotic strains lies in better molecular research fol-
lowed by multiple well-performed clinical trials. For example,
two more recent clinical trials used well-characterized probiotic
strains for the treatment of BV (Anukam et al., 2006b; Mastro-
marino et al., 2009) (Table 1). In the first study, L. rhamnosus
GR-1 and L. fermentum RC-14 (now known as L. reuteri RC-14)
were vaginally administrated (Anukam et al., 2006b). Both strains
are well-known probiotic strains with well documented adhesion
capacity to vaginal and uroepithelial cells, as well as capacity to
inhibit adhesion and growth of uropathogens (Reid et al., 1987).
In addition, L. reuteri RC-14 produces biosurfactant compounds
(Velraeds et al., 1998) and significant amounts of H2O2 (Reid
et al., 2001). The strains were also successfully recovered from the
vaginal niche after oral administration and were shown to persist
in the vaginal niche for 19 days post administration (Gardiner
et al., 2002). Anukam et al. (2006b) compared the effect of intrav-
aginally introduced capsules of L. rhamnosus GR-1 and L. reuteri
RC-14 withmetronidazole gel and reported a BV cure rate of 65%
in the probiotic group in comparison to 33% in the metronida-
zole treated group (Anukam et al., 2006b). A few follow up studies
with HIV patients showed that L. rhamnosus GR-1 and L. reuteri
RC-14 were able to reduce episodes of diarrhea, nausea and flatu-
lence (Anukam et al., 2008; Irvine et al., 2010) and to increase the
CD4+ counts in several patients (Hummelen et al., 2011).
In addition to L. rhamnosus GR-1 and L. reuteri RC-14, oth-
ers also used well-characterized and rationally selected vaginal
Lactobacillus strains. For instance, an Italian group investigated
capsules containing at least 109 CFU of L. brevis CD2, L. salivar-
ius subsp. salicinius FV2, and L. plantarum FV9 (Mastromarino
et al., 2009) after intravaginal introduction using a commercially
available product. As described above, the strains were reported
to possess anti-pathogenic effect against C. albicans, G. vaginalis,
HSV-2, and C. trachomatis (Mastromarino et al., 2002, 2011,
2014; Conti et al., 2009), and were able to colonize the human
vagina (Massi et al., 2004). The authors observed that in the
probiotic-treated group, the BV cure rate was 50% compared to
only 6% in the placebo-treated group with the combined diagnos-
tic methods (using Amsel criteria and Nugent scores), whereas a
67% vs. 12% cure rate was obtained when considering only the
Amsel criteria (Mastromarino et al., 2009).
Treatment of BV Using Probiotic Therapy in
Combination with Antibiotic Therapy
Other studies investigate the role of probiotic treatment follow-
ing standard antibiotic treatment (Table 1). The first study eval-
uates the BV cure rate after introducing freeze-dried strains of
L. gasseri, L. casei subsp. rhamnosus and L. fermentum impreg-
nated on tampons during menstruation (Eriksson et al., 2005).
Each of the women received first clindamycin ovules vaginally
once daily for 3 days, followed by probiotic treatment during
the next menstruation period. However, the authors did not
observe significant BV cure rates after the second menstruation
in comparison to the control placebo group. The negative out-
come might have multiple reasons, such as the number and the
duration of the used tampons, the chosen strains, and the low
concentration of Lactobacillus at the end of the study (only 106
CFU/ml). Furthermore, as described above, the VMB drastically
shifts during menstruation which can be the other possible expla-
nation for the lack of effects observed by Eriksson et al. since
the authors administrated the probiotics during menstruation.
Anukam et al. (2006a) evaluated the augmentation of antimi-
crobial metronidazole therapy for BV by a 30-day oral probiotic
treatment using L. rhamnosus GR-1 (109 CFU/ml) and L. reuteri
RC-14 (109 CFU/ml). After 30-day treatment, 88% of the patients
were cured in the antibiotic/probiotic group compared to 40% in
the antibiotic/placebo group. The good record of L. rhamnosus
GR-1 and L. reuteri RC-14 was also observed by Martinez et al.
(2009) who used vaginal capsules containing the two strains in
combination with a single dose of tinidazole (2 g). The authors
observed that the probiotic group had a significantly higher cure
rate of BV (87.5%) than the placebo group (50.0%). Additionally,
according to the Nugent score, more women were assessed with
normal VMB in the probiotic group (75.0 vs. 34.4% in the placebo
group) (Martinez et al., 2009). Petricevic and Witt (2008) were
also able to show restoration of the VMB after antibiotic treat-
ment of BV and exogenously applied L. casei Lcr35 (109 CFU/ml).
Larsson et al. (2008) studied the effect of two probiotic strains
introduced vaginally for 10 days during 3 menstrual cycles in
a double blind, randomized, placebo-controlled trial. The lacto-
bacilli used were commercially available as EcoVag R© vaginal cap-
sules (Bifodan A/S, Denmark) containing L. gasseri (Lba EB01-
DSM 14869) with a concentration of 108−9 CFU/capsule and
L. rhamnosus (Lbp PB01-DSM 14870) with a minimal concen-
tration of 108−9 CFU/capsule. The study did not show a positive
effect of the supplementary treatment with probiotic lactobacilli
during the first month. However, a significantly reduced recur-
rence rate of BV at 6 months after the start of the treatment was
observed (Larsson et al., 2008). Another more recent study also
investigated the effect of probiotic treatment during a period of
6 months (Bradshaw et al., 2012). The authors used 107 CFU/ml
of live L. acidophilus KS400 introduced by a single vaginal pes-
sary for 12 nights, but did not observe reduced BV recurrence.
Finally, since L. crispatus species are often isolated from healthy
vaginal niches, strains of this species hold great potential as probi-
otic, such as L. crispatus CTV-05 (LACIN-V), which appears safe
in early clinical studies and is able to colonize the vaginal niche
(Hemmerling et al., 2009, 2010).
It thus appears that only specific strains and treatment reg-
imens show a beneficial effect of probiotics in BV treatment.
Of note, the first conducted systematic review (only based on
4 studies) did not provide conclusive evidence that probiotics
can enhance or are better than antibiotics in the treatment of
BV (Senok et al., 2009). However, a more recent meta-analysis
concluded that probiotics show a beneficial effect in patients
who are suffering from BV, based on the included 12 clinical
trials (summarized in Table 1) (Huang et al., 2014). One of the
advantages of using probiotics unlike antibiotics is the fact that
these beneficial bacteria can be used over a long period of time
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without interfering with the normal VMB. Therefore, probiotics
cannot only be used for single treatment of BV but also for
the prevention of BV recurrence in healthy women with a his-
tory of recurrent BV. For example, Ya et al. (2010) evaluated
the effect of vaginal probiotic capsules (Probaclac Vaginal; Nicar
Laboratories, Inc, Blainville, Quebec, Canada) on BV prophy-
laxis in healthy women with a history of recurrent BV in a ran-
domized, placebo-controlled, double-blinded study. Between the
2- and 11-month follow up period, women who received pro-
biotics reported lower recurrence rates of BV and G. vaginalis
(Ya et al., 2010).
Conclusions
Several culture-dependent and independent studies highlight the
importance of vaginal lactobacilli for a healthy vaginal ecosystem.
With the costs of molecular techniques steadily decreasing, it can
be anticipated that molecular detection of the presence of lacto-
bacilli at the species or even strain level could gain importance
in clinical settings and might form important complementary
approaches to the current Nugent and Amsel scoring methods,
which could facilitate the use of lactobacilli as a vaginal health
biomarker in the clinical setting. Over the last 10 years, NGS
techniques have provided a more complete picture of the total
bacterial diversity in the vaginal environment. Therefore, the def-
inition of a healthy and normal vaginal microbiota has been
re-considered. An emerging number of studies report the pres-
ence of non-Lactobacillus dominated VMBs, which potentially
corresponds to so called asymptomatic BV, dominated by “BV-
associated bacteria”. These asymptomatic cases of BV can explain
why the treatment of recurrent BV is often unsuccessful. How-
ever, the same bacterial species have been also associated with
the development of symptomatic BV, although the factors which
trigger this condition are largely unknown. It is also question-
able whether the “BV-associated bacteria” are really pathogenic
and therefore possess pathogenic properties, or whether the host
triggers environmental changes which activate different bacterial
responses able to develop infection. The definition of a healthy
and normal VMB is even more complicated when introduc-
ing STIs, which are clearly disease stages. Predisposition for
many STIs has been directly linked to an unhealthy and abnor-
mal microbiota, although STIs have also been associated with
a healthy and normal VMB, suggesting that different types of
microbiota might lead to different degrees of predisposition to
STIs. Follow up studies are thus strongly required in order to
understand the true role of the host and its microbiota in the pro-
cess of STIs. Therefore, a healthy vaginal microbiota is not merely
characterized by the presence of community types, but it is rather
characterized by its beneficial function to the host and absence
of symptoms, which can be provided by various vaginal types of
microbiota, with or without lactobacilli.
Even if lactobacilli are not absolutely required for a
healthy VMB, the fact that 70% of healthy women have a
Lactobacillus-dominated microbiota, identified even using NGS
techniques, highlights that the targeted and personalized appli-
cation of Lactobacillus-based vaginal probiotics is still very valid.
Successful administration of probiotics to the vaginal niche and
treatment of BV will nevertheless depend on the exact Lacto-
bacillus strain(s) used, applied dose, formulation, combination
with standard antibiotic treatment, time of administration and
duration of the treatment. To determine whether subjects are
responders or non-responders to probiotic treatments, specific
variables such as race, age of the subjects and dominant VMB
might play key roles. Also, large-scale well-designed clinical tri-
als with standardized protocols (consistency regarding species,
dosage, route, timing and duration of administration) are of
great importance to enable direct comparison between different
probiotics.
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